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safety, and the secondary endpoints were immunological 
and clinical responses.
Results Vaccinations with HIG2-9-4 peptide could be well 
tolerated without any serious systemic adverse events. 
Peptide-specific cytotoxic T lymphocyte (CTL) responses 
were detected in eight of the nine patients. Doses of 1.0 or 
3.0 mg/body seemed to induce a CTL response better than 
did a dose of 0.5 mg/body, although the number of patients 
was too small to draw a firm conclusion. The disease con-
trol rate (stable disease for ≥4 months) was 77.8 %, and the 
median progression-free survival time was 10.3 months.
Conclusions HIG2-9-4 peptide vaccine treatment was tol-
erable and effectively induced peptide-specific CTLs in 
RCC patients. This novel peptide vaccine therapy for RCC 
is promising.
Keywords Cancer peptide vaccine · Genome-wide 
expression profile · Cytotoxic T lymphocyte · Renal cell 
carcinoma
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BIMAS  BioInformatics and molecular analysis section
BLAST  Basic local alignment search tool
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GMP  Good manufacturing practice
HIG2  Hypoxia-inducible protein 2
HLA  Human leukocyte antigen
IFN  Interferon
OS  Overall survival
PBMC  Peripheral blood mononuclear cell
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Abstract 
Purpose Through genome-wide expression profile analy-
sis, hypoxia-inducible protein 2 (HIG2) has previously 
been identified as an oncoprotein involved in develop-
ment/progression of renal cell carcinoma (RCC). We 
subsequently identified a highly immunogenic HLA-
A*0201/0206-restricted epitope peptide (HIG2-9-4) corre-
sponding to a part of HIG2 and applied it as a therapeu-
tic vaccine. We conducted a phase I clinical trial using the 
HIG2-9-4 peptide for patients with advanced RCC.
Materials and Methods Nine patients having HLA-
A*0201 or HLA-A*0206 with metastatic or unresectable 
RCC after failure of the cytokine and/or tyrosine kinase 
inhibitor therapies were enrolled in this study. The patients 
received subcutaneous administration of the peptide as an 
emulsion form with Montanide ISA-51 VG once a week 
in a dose-escalation manner (doses of 0.5, 1.0, or 3.0 mg/
body, 3 patients for each dose). The primary endpoint was 
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PFS  Progression-free survival
RAI  Reactions at the injection sites
RCC  Renal cell carcinoma
RECIST  Response evaluation criteria in solid tumors
SD  Stable disease
TKI  Tyrosine kinase inhibitor
Treg  Regulatory T cell
TUMAP  Tumor-associated peptide
Introduction
The majority (70 %) of patients with renal cell carcinoma 
(RCC) and metastatic disease are managed non-surgi-
cally, whereas approximately 30 % undergo cytoreductive 
nephrectomy [1, 2]. The classical standard therapy for met-
astatic RCC (mRCC) was cytokine-based immunotherapy 
with IL-2 and/or IFN-α that exhibited few durable complete 
remissions [3, 4]. Molecular-targeted therapies have been 
recently developed as novel standard treatments for mRCC. 
However, despite their significant anti-tumor effects, only 
a small subset of patients can be cured and the majority of 
patients suffer from very severe adverse reactions, includ-
ing hand-foot syndrome, liver dysfunction, and interstitial 
pneumonia. Therefore, development of a novel anti-cancer 
drug for mRCC is eagerly expected.
Since RCC is one of the most immunoresponsive can-
cers in humans, immunotherapy has been considered to be 
a promising treatment strategy against RCC. Progress in 
biomedical research over the last two decades has provided 
several options for cancer immunotherapy. These include 
non-specific immune activation by cytokines, passive 
immunotherapy with specific antibodies to block immune 
checkpoint molecules, active immunotherapy that induces 
cytotoxic T cells with oncoantigen peptides or neoanti-
gens [5], and T cell receptor-engineered adaptive immu-
notherapy [6]. Cancer peptide vaccines are comprised of 
short or long amino acid sequences as tumor antigens com-
bined with a vaccine adjuvant. Thus, they fall broadly into 
the category of defined antigen vaccines. In this study, we 
applied a novel therapeutic peptide vaccine derived from 
hypoxia-inducible protein 2 (HIG2) to activate RCC-spe-
cific cytotoxic T lymphocytes (CTLs).
We previously reported HIG2 as an oncofetal protein 
that was highly expressed in RCC and fetal kidney as 
determined by genome-wide expression profile analysis 
[7]. Because HIG2 expression was specific to RCC and 
had an expression that was hardly detectable in normal 
organs, we considered HIG2 to be a good candidate for the 
development of molecular-targeted therapies against RCC. 
As one of the approaches to develop anti-HIG2 drugs, we 
screened and identified a human leukocyte antigen (HLA)-
A*0201/0206-restricted epitope peptide, named HIG2-9-4 
peptide that could have a high antigenic activity to induce 
CTLs [8]. So, far, several peptide epitopes derived from 
cancer-testis antigens or oncofetal proteins have been 
investigated in translational research targeting several types 
of human cancer [9–17]. We conducted a Phase I clinical 




HIG2-derived 9- and 10-mer peptides that have high bind-
ing affinity to HLA-A:*02:01 were identified as candi-
dates by using the binding prediction software, BioInfor-
matics and molecular analysis section (BIMAS), and the 
homologous sequences were screened by using the homol-
ogy search program, basic local alignment search tool 
(BLAST), as previously reported [8]. The selected high-
affinity peptide, HIG2-9-4 peptide (VLNLYLLGV), was 
manufactured as good manufacturing practice (GMP) grade 
at a purity of >95 % for the clinical trial by the American 
Peptide Company Inc. (Sunnyvale, CA). HLA-A*0201-
restricted HIV-derived epitope peptide (ILKEPVHGV) was 
also synthesized by American Peptide Company Inc., for 
control measurements of the CTL response.
Clinical study design
This study was a non-randomized, open-label, phase I clini-
cal trial involving dose-escalation of the HIG2-9-4 peptide 
for patients with advanced RCC. The primary endpoint was 
safety of this novel peptide vaccine, and the secondary end-
points were immunological responses, clinical outcomes, 
and the determination of the optimal dose for further clinical 
trials. Immunological responses were evaluated by meas-
uring interferon (IFN)-γ production from specific CTLs 
responding to the HIG2-9-4 peptide and immunological 
reactions at the injection sites (RAI). RAI was defined by 
erythema and/or induration at the injection site of the pep-
tide vaccine. Clinical outcomes were assessed by computed 
tomography (CT) scanning results in accordance with the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria (version 1.1), progression-free survival (PFS), and 
overall survival (OS). CT scanning was performed within 
1 month before the vaccination and after every course of the 
vaccination. PFS and OS curves were estimated by using 
Kaplan–Meier methodology. PFS was determined as the 
time from the date of the initial vaccination until the deci-
sion of disease progression. OS was calculated from the 
date of the initial vaccination to the date of death. This trial 
was registered in ClinicalTrials.gov (No. NCT01254838).
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Patient eligibility
Patients with pathologically confirmed clear-cell RCC that 
progressed after standard therapy, such as surgical resec-
tion, cytokine treatment, or molecular-targeted therapy 
(sorafenib or sunitinib), were enrolled in this trial from 
November 2008 to August 2009 at Iwate Medical Uni-
versity and Kochi Medical School. The eligibility crite-
ria were (1) unresectable mRCC, recurrent and/or locally 
advanced disease diagnosed by imaging analysis, (2) 
HLA-A*0201 or 0206 genotype, (3) an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0–2, 
(4) age 20–79 years and life expectancy of ≥3 months, (5) 
adequate hepatic, renal, and bone marrow function (white 
blood cell count of ≥2000/μL, platelets of ≥75,000/μL, 
aspartate aminotransferase of ≤50 IU/L, alanine ami-
notransferase of ≤150 IU/L, total bilirubin of ≤3 g/dL, 
and serum creatinine of ≤1.5 mg/dL), and (6) no other 
immunotherapy, molecular target therapy, or radiotherapy 
within 4 weeks before the vaccination. The exclusion cri-
teria were (1) active infection, other active malignancy, (2) 
pregnancy or lactation, and (3) treatment with immunosup-
pressive agents (e.g., steroids). All patients were informed 
of the investigational nature of the study and gave written 
informed consent, in accordance with each institutional 
review board.
Treatment protocol
A skin test was performed before the first vaccination by 
intradermal injection of 10 μg of the peptide, to avoid the 
risk of acute hypersensitivity. A positive skin reaction was 
defined as a >30-mm diameter of erythema and induration 
relative to that of the negative control using saline. The 
dose was escalated as 0.5, 1, and 3 mg/body of the peptide 
vaccine. The HIG2-9-4 peptide was emulsified by using 
incomplete Freund’s adjuvant (Montanide ISA-51 VG, 
Seppic, Paris, France). The vaccination was given subcu-
taneously once a week, and four weeks as 1 cycle. After a 
1-week interval, the next cycle was performed and contin-
ued as a vaccine monotherapy until the judgment of pro-
gressive disease (PD) or doctor’s assessment.
Clinical monitoring and toxicity assessment
Baseline studies included physical examination, blood 
examination, and CT scan image analysis. All patients were 
followed up until death, intolerance, or the patient’s with-
drawal of consent. Toxicity assessments were performed at 
least once a week by applying the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 
3.0. Dose-limiting toxicity was defined as a hematological 
toxicity of grade ≥4, and non-hematologic toxicity of grade 
≥3. Clinical and laboratory assessments were checked at 
each visit.
Measurement of CTL response in clinical study
IFN-γ enzyme-linked immunospot (ELISPOT) kit and 
AEC substrate set (BD Pharmingen, San Diego, CA) were 
used to measure CTL responses in the clinical study, as 
reported previously [14]. Peripheral blood mononuclear 
cells (PBMCs) were obtained from patients and were fro-
zen before vaccination and at the end of each course. Fro-
zen PBMCs were thawed and used for in vitro sensitiza-
tion. Briefly, PBMCs were cultured in 1 mL of complete 
media (prepared with a mix of AIM-V and RPMI, 50 % of 
each) containing 10 % fetal bovine serum in a 48-well plate 
with 10 μg/mL of HIG2-9-4 peptide and 20 IU/mL of IL-2 
at 37 °C with 5 % CO2, for 2 weeks. On day 7, half of the 
medium was removed from each well and 500 μL of fresh 
medium containing epitope peptide, as described above, 
was added to sensitize. After a 2-week incubation, CD4-
positive cells were removed by using a Dynal CD4 posi-
tive isolation kit (Invitrogen, Carlsbad, CA, USA), and har-
vested cells were co-cultured with peptide-pulsed T2 cells 
(1 × 105 cells per well) at 37 °C for 20 h. HLA-A*0201-
restricted HIV-derived epitope peptide (ILKEPVHGV) was 
used as the control peptide. ELISPOT assay was performed 
in triplicate. HIG2-9-4-specific CTL response was defined 
according to an evaluation tree algorithm [15].
Results
Patients’ characteristics
A total of nine patients, three each for the 0.5, 1, and 
3.0 mg/body cohorts, were enrolled in this trial. The clini-
cal characteristics of these nine patients are shown in 
Table 1. The performance status was 0 for four patients, 
1 for four patients, and 2 for one patient. According to 
the MSKCC risk criteria, four patients were intermediate 
risk and five patients were poor risk. Prior to the vaccine 
treatment, all patients except one had received cytokine 
therapy (interferon-α or/and interleukin-2), five received 
TKI treatment (sorafenib and/or sunitinib) in addition 
to the cytokine therapy and one received sorafenib treat-
ment. The duration of previous treatments varied widely 
(4–26 months). Six patients had discontinued previ-
ous treatment for PD, and three patients had stopped the 
treatment because of an adverse event (AE). All previous 
cytokine therapies were discontinued because of PD. The 
evaluable lesions were lung metastasis in eight patients, 
pancreatic metastasis in three patients, and local recur-
rence lesions in two patients.
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Toxicity
No hematologic, cardiovascular, hepatic, or renal toxici-
ties were observed during and after the vaccine therapies 
(Table 2). The number of vaccinations for each patient 
ranged from 4 to 88 (average, 37.4). Six patients exhibited 
RAI, including erythema and induration at the injection 
sites. RAI was observed when the number of vaccinations 
was ≥20 times. All of these six patients who exhibited RAI 
were judged as having stable disease (SD) condition for 4.4–
25.9 months (Table 2). On the other hand, two patients with 
PD at a very high stage showed no sign of RAI. The number 
of patients in our study was too small to confirm an associa-
tion between the development of RAI and clinical efficacy.
Clinical responses
Seven patients maintained SD through five courses of 
vaccination, and the remaining two showed PD within 3 
courses, according to the RECIST criteria (Table 2). The 
disease control rate (all were SD) was 77.8 % in this study. 
CT scan images of one representative patient with long SD 
are shown in Fig. 1. Although multiple lung metastases 
were present at the beginning of the treatment, this patient 
maintained good performance status and stable condi-
tion of these metastatic lesions for nearly 26 months, and 
showed no signs of severe adverse events, except RAI. The 
Kaplan–Meier curves for PFS and OS are shown in Fig. 2. 
The median PFS was 10.3 months, and the median OS was 
25.8 months. When patients had undergone a long period 
of previous treatment, they tended to show longer survival 
after vaccine therapy.
CTL response
An IFN-γ ELISPOT assay using PBMCs was obtained 
from the patients to assess CD8+ T cell immune responses 
to the HIG2-9-4 peptide. The representative data of the 
IFN-γ ELISPOT assay in patient 5 after one course (four 
injections) of the treatment are shown in Fig. 3. The posi-
tive CTL responses were observed in two of the three 
patients receiving 0.5 mg/body of the vaccination (one 
showed strong response and the other showed very weak 
response). All six patients who received 1.0 mg/body or 
3.0 mg/body showed strong HIG2-peptide-specific T cell 
induction (Table 2). Most cases, except for one (patient No. 
1), showed CTL induction very early within 1–2 courses 
after the vaccination. In total, positive CTL responses were 
observed in eight of the nine patients. Notably, all seven 
patients who showed strong activation of peptide-specific 
CTLs maintained SD condition for ≥4 months.
Discussion
HIG2 has been identified as an oncofetal protein that is 
expressed highly and specifically in RCC and fetal kidney 
tissues, which implies that the HIG2 protein could be an 
attractive molecular target for development of novel treat-
ment for RCC [7]. As one of the approaches to develop a 
novel treatment option, we previously developed the HLA-
A*0201/0206-restricted HIG2-derived epitope peptide, 
HIG2-9-4 [8]. In the present study, we conducted a phase 
I clinical trial using the HIG2-9-4 peptide for patients with 
advanced RCC. The HIG2-peptide vaccine therapy was 
well tolerated and induced the peptide-specific CTLs very 
effectively. Among three different dose groups (0.5, 1.0, 
and 3.0 mg), the peptide-specific CTL responses in the 
higher dose groups were stronger than those in the 0.5-
mg peptide group, although the number of patients was 
too small to draw a definite conclusion. However, since 
no dose-limiting toxicities were observed, we suggest that 
the optimal dose of this peptide for further clinical trials is 
3.0 mg/body.
Table 1  Enrolled patient characteristics
Case Age Sex PS MSKCC criteria Pre-vaccine treatment Duration of the previous 
treatment (months)
Reason of stop the pre-
vaccine treatment
Evaluable lesion
1 68 F 0 Intermediate IFN-α, sorafenib 26 AE Lung
2 57 M 1 Poor IFN-α, IL-2, sorafenib 6 PD Lung
3 50 M 2 Poor IFN-α, sunitinib 4 PD Local recurrence
4 74 M 1 Poor IFN-α, IL-2, sorafenib 10 AE Lung, pancreas
5 68 M 1 Poor IFN-α 8 PD Lung
6 48 M 1 Poor IFN-α, IL-2, sorafenib, 
sunitinib
11 PD Lung, pancreas, local 
recurrence
7 60 M 0 Intermediate Sorafenib 10 AE Lung
8 74 M 0 Intermediate IFN-α, IL-2 14 PD Lung, pancreas
9 65 M 0 Intermediate IFN-α 22 PD Lung
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Among the nine patients enrolled in this study, strong 
peptide-specific CTL responses were induced in seven 
patients, all of whom maintained SD for ≥4 months. How-
ever, two patients with no or weak immune response devel-
oped PD very quickly. This result might suggest that induc-
tion of HIG2-9-4 peptide-specific CTLs could contribute to 
better clinical outcomes.
When our clinical trial started, the molecular-targeted 
therapies using sorafenib and sunitinib for mRCC had 
just been approved in our country. Therefore, the patients 
who enrolled in this trial received cytokine therapy and/
or TKI therapy before enrollment. A phase III study of 
sorafenib for patients with cytokine-refractory advanced 
RCC reported a median PFS of 5.5 months [18]. Moreo-
ver, a phase III study of sunitinib for RCC patients who 
had no previous systemic therapy reported a median PFS of 
11.0 months [19]. The median PFS in our study was calcu-
lated to be 10.3 months. Our result was consistent with the 
results of sorafenib and sunitinib, although tumor shrinkage 
was not observed in any of the nine patients treated with the 
HIG2 vaccine. In this study, none of the enrolled patients 
had liver, bone, or brain metastases. We might consider this 
group of RCC patients as ideal for peptide vaccine therapy.
Several RCC-associated antigens as well as HLA-class 
I-restricted epitope peptides have been previously reported 
[20]. However, only a limited number of clinical stud-
ies using the peptide-based vaccine for RCC have been 
reported [21–27], and the clinical benefit of vaccine therapy 
for RCC is likely to be limited to a small subset of patients. 
Walter et al. reported phase I/II clinical trials using multiple 
tumor-associated peptides (TUMAPs called IMA901) [28]. 
They treated a total of 96 HLA-A02-positive patients with 
mRCC, using IMA901. In the phase I part, they showed an 
association of T-cell responses to multiple TUMAPs with 
better disease control. In the randomized phase II part, they 
demonstrated that cyclophosphamide administration before 
IMA901 reduced the number of regulatory T cells (Tregs), 
and that immunological response of the patients to multiple 
TUMAPs was associated with longer survival. However, a 
randomized phase III study to confirm the clinical benefit 
was reported to have given negative results more recently. 
A G250 monoclonal antibody has also been identified for 
an RCC-associated antigen, which was later proven to be 
identical to carbonic anhydrase protein (CA IX) [29]. A 
Phase III clinical trial as an adjuvant treatment of clear-cell 
RCC after nephrectomy demonstrated a significant benefit 
of prolonged disease-free survival in patients with high CA 
IX score in the resected RCC, compared with patients in 
the placebo [30]. Cancer immunotherapy, including peptide 
vaccine therapy, may be more effective for patients with a 
postoperative adjuvant therapy or minimum disease status.
Molecular-targeted therapy is effective in advanced 
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severe AEs. These include hypertension, hand–foot skin 
reaction, fatigue, diarrhea, anemia, and thrombocytope-
nia, which decrease the quality of life for patients and 
may sometimes lead to life-threatening conditions. On the 
other hand, although the peptide vaccine treatment does 
not cause any severe systemic AEs in general, only a sub-
set of patients can expect a clinical benefit. In addition, at 
present, immune checkpoint blockades, such as anti-PD-1/
PD-L1 or anti-CTLA-4 antibodies, are considered to be 
the most promising drugs for treatment of advanced cancer 
patients. For this type of treatment, the presence of CTLs 
that recognize a cancer-specific antigen(s) with an HLA 
class I molecule on cancer cells is now suggested to be a 
critical predictor of better clinical outcomes. Particularly, 
CTLs recognizing neoantigens that are generated by the 
somatic mutations that occur in cancer cells are considered 
to be strong inducers for CTLs in cancer tissues [31, 32].
However, CTLs specifically recognizing oncoantigen 
peptides such as HIG2, which are broadly expressed in can-
cer cells but not in normal cells, may also contribute to the 
clinical outcome of immune checkpoint blockade therapies. 
At this moment, although neoantigens are certainly more 
Fig. 1  Chest CT image of a long SD case. Chest CT image of case 1, showing multiple lung metastases as indicated by arrows before the vac-
cine treatment. After 2 and 12 courses of peptide vaccine (0.5 mg/body) treatment, the sizes of multiple lung metastases were unchanged
Fig. 2  Kaplan–Meier estimates 
of progression-free survival 
(a) and overall survival (b) 
following HIG2 peptide vaccine 
therapy. The median PFS and 
OS are 10.3 and 25.8 months, 
respectively
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cancer-specific than oncoantigen-derived peptides, we still do 
not know which induce a higher level of anti-tumor immune 
response in cancer patients. In addition, it is also certain that 
HLA-restricted cancer peptide vaccines derived from oncoan-
tigens can be more widely applied to a larger subset of can-
cer patients, than can individualized neoantigens. We suspect 
that the combination of an immune checkpoint blockade with 
CTL-inducing active immunotherapy and either neoantigens 
or oncoantigens could enhance the clinical benefit.
In summary, HIG2-9-4 peptide vaccine treatment was 
tolerable and effectively induced peptide-specific CTLs in 
RCC patients. This novel peptide vaccine therapy for RCC 
appears to be promising.
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